Trial Profile
Exploratory Study to Evaluate the Safety and Efficacy of CD5789 in Subjects with Early Stage Cutaneous T-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Trifarotene (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions
- 16 Mar 2015 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
- 13 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.